Single‐center experience with self‐expanding transcatheter aortic valve system for symptomatic high‐risk patients with severe aortic regurgitation: One‐year outcomes

• Published in: Catheterization and cardiovascular interventions 2024-11, Vol.104 (6), p.1275-1280
• Main Authors: Kong, Xiang‐Quan, Zhang, Juan, Gao, Xiao‐Fei, Wang, Zhi‐Mei, Ye, Peng, Zhang, Jun‐Jie, Chen, Shao‐Liang
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; aortic regurgitation; Aortic valve; Aortic Valve - diagnostic imaging; Aortic Valve - physiopathology; Aortic Valve - surgery; Aortic Valve Insufficiency - diagnostic imaging; Aortic Valve Insufficiency - etiology; Aortic Valve Insufficiency - mortality; Aortic Valve Insufficiency - physiopathology; Aortic Valve Insufficiency - surgery; Cardiac Pacing, Artificial; device success; Female; Heart; Heart Valve Prosthesis; Hemodynamics; Hospital Mortality; Humans; Male; Middle Aged; Mortality; Patients; Prosthesis Design; Recovery of Function; Regurgitation; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Thorax; Time Factors; transcatheter aortic valve implantation; Transcatheter Aortic Valve Replacement - adverse effects; Transcatheter Aortic Valve Replacement - instrumentation; Transcatheter Aortic Valve Replacement - mortality; Treatment Outcome; Ventricular Function, Left; VitaFlow system
• ISSN: 1522-1946; 1522-726X; 1522-726X
• DOI: 10.1002/ccd.31193

Aims To evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) for the treatment of aortic regurgitation (AR). Methods From September 2019 to February 2022, 62 patients who underwent transfemoral TAVI procedure for pure, symptomatic severe AR with the VitaFlow system were enrolled in the current study. The outcomes were assessed according to the Valve Academic Research Consortium 3 criteria. Procedural results and clinical outcomes for 1 year were analyzed. Results The mean age was 71.56 ± 7.34 years and 58.1% were male. The mean Society of Thoracic Surgeons score was 5.44 ± 3.22%. The device success rate was 79.0%. Only one patient was converted to open surgery. The in‐hospital mortality rate was 1.6%. The 1‐year all‐cause mortality rate was 6.5%. The new permanent pacemaker implantation rate was 29.0% in‐hospital and 30.7% at 1‐year follow‐up. The second valve implantation rate was 14.5%. No patient developed more than moderate paravalvular leakage during follow‐up. The mean ejection fraction improved from 54.05 ± 10.83% at baseline to 59.32 ± 8.70% (p